Showing 3941-3950 of 8681 results for "".
- Veradermics Gets New Financing for AGA/PHL Candidatehttps://practicaldermatology.com/news/veradermics-gets-new-financing-agaphl-candidate/2468761/Veradermics announced the closing of a $75 million Series B financing, proceeds of which will be used to fund the ongoing clinical development of the company’s lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL). "The initiation of our pivota
- Melasma Clinical Trials Show Advancements in Inclusive Representationhttps://practicaldermatology.com/news/melasma-clinical-trials-show-advancements-inclusive-representation/2468760/A new analysis of melasma clinical trials indicates progress toward inclusivity, with broad gender, racial, and Fitzpatrick skin type (FST) representation. Researchers publishing in the Journal of Drugs in Dermatology analyzed melasma clinical trials listed on ClinicalTrials.gov,
- FDA Clears Illuminate PRP System for Clinical Usehttps://practicaldermatology.com/news/fda-clears-illuminate-prp-system-clinical-use/2468757/Illuminate PRP’s platelet-rich plasma (PRP) system has received FDA clearance for clinical use, the company announced. The FDA-cleared single-spin PRP system offers a fast, efficient method for preparing high-quality PRP with high platelet capture rates, providing physicians with a reliabl
- Analysis: DSP Gene Variants in PPK Linked to Cardiomyopathy Riskhttps://practicaldermatology.com/news/analysis-dsp-gene-variants-ppk-linked-cardiomyopathy-risk/2468747/A Danish cohort study suggests genetic testing is crucial in accurately diagnosing and subclassifying palmoplantar keratoderma (PPK), a condition
- Study: Cutaneous Lupus Linked With Elevated Cardiovascular Disease Riskhttps://practicaldermatology.com/news/study-cutaneous-lupus-linked-elevated-cardiovascular-disease-risk/2468723/Patients with cutaneous lupus erythematosus (CLE) face an elevated risk of atherosclerotic cardiovascular disease (ASCVD), comparable to that seen in systemic lupus erythematosus (SLE), according to a new study. Authors of the retrospective cohort study analyzed health records of 8,138 pat
- Almirall Announces Scientific Research Hub at R&D Centerhttps://practicaldermatology.com/news/almirall-announces-scientific-research-hub-rd-center/2468710/Almirall announced the launch of “The Hive,” a novel scientific research hub located at its R&D center in Barcelona, Spain. According to a press release, the Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s
- Xylazine Wounds: Chronicity Linked to Necrosishttps://practicaldermatology.com/news/xylazine-wounds-chronicity-linked-necrosis/2468631/Xylazine-associated wounds frequently present on extremities with necrotic wound beds and increase in severity with chronicity, according to a systematic case series published in JAMA Dermatology. The case series was conducted across three academic hospitals looking at clinical characteris
- Analyses: Ruxolitinib Cream Reduces AD Symptom Burden in 12 Hourshttps://practicaldermatology.com/news/analyses-ruxolitinib-cream-reduces-ad-symptom-burden-12-hours/2468615/Ruxolitinib cream significantly reduced skin pain and improved patient-reported outcomes (PROs) in individuals with mild-to-moderate atopic dermatitis (AD), with improvements sustained over 52 weeks, according to data from the TRuE-AD1 and TRuE-AD2 studies. Researchers the results publishi
- Botanix Announces Expanded Payer Coverage for Sofdrahttps://practicaldermatology.com/news/botanix-announces-expanded-payer-coverage-sofdra/2468602/Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis. According to a press release from Botanix, Ascent represents approximat
- Roflumilast Cream 0.15% Receives Glamour's Best Eczema Product Award for 2024https://practicaldermatology.com/news/roflumilast-cream-015-receives-glamours-best-eczema-product-award-2024/2468585/Arcutis Biotherapeutics announced today that ZORYVE® (roflumilast) cream 0.15% has been named Best Eczema Product by Glamour magazine in its 2024 Health and Wellness Awards. The cream, which is the first once-daily FDA-approved topical treatment specifically indicated for mild to